tradingview
Sagimet to advance denifanstat Phase 3 in US; $104.5M cash, $175M offering funds operations through 2028
Sagimet updated an investor slide presentation highlighting denifanstat Phase 3 plans for US acne in 2H 2026, clinical data and financial runway.Key Highlights:Original SEC Filing: Sagimet Biosciences Inc. [ SGMT ] - 8-K - Jul. 20, 2026This is an AI-powered summary. It may contain inaccuracies. Con…
